Sign In 
Sign In
Sign In
Rucha Wankhede
Biochemical
16 Mar 2017
MammoAlert - a novel device paves way to diagnose Breast Cancer in minutes
In what could prove to be a promising breakthrough in medical field, a California-based POC (Point of Care) Medical Systems Inc on Wednesday unveiled a rapid, portable breast cancer screening test known as MammoAlert, based on its Pandora CDx micro fluidic, serum screening-based platform.
The technology provides for a simultaneous molecular test for the presence of 90 serum markers at the point of care and hence is ideal for screening capabilities for life-threatening diseases like Cancer, Cardiovascular disorders, Infectious diseases etc. The novel device estimates specific protein markers present in the woman’s blood sample.
Breast cancer is the most common cancer among women in India with highest numbers in the age group of 50-60. With over 1.5 lakh women being diagnosed with breast cancer, around 70,000 deaths are being reported every year. Taking this into consideration, POC’s technology platform renders testing accessible to 96.3% of women who need to be screened annually. The portable breast cancer screening test, which runs on Pandora CDx technology, uses a simple drop of blood to generate results in 15 minutes. Using multiple cancer markers it claims to exhibit a sensitivity of 0.91and specificity of 1 which implies an accuracy of over 95 per cent and a false positive rate of zero.
At the launch of the device in Maharashtra, State Health minister Dr Deepak Sawant quoted that a pilot is to be run in the state, in the areas where the incidence of breast cancer is high. The acceptance rate of the test is also likely to be more given that it just requires a simple blood test as opposed to exposing of women required for mammography. The taboo of undressing serves as a biggest deterrent for screenings in India, apart from high cost. The operation of the low cost device is easy too, where a technician can operate the machine and data could be sent via mobile devices to a cloud platform. This can then be accessed by a doctor who can contact the patient, explained Sanjeev Saxena, CEO, POC Medical Systems.
Source: POC MedicalSystems via HT
The technology provides for a simultaneous molecular test for the presence of 90 serum markers at the point of care and hence is ideal for screening capabilities for life-threatening diseases like Cancer, Cardiovascular disorders, Infectious diseases etc. The novel device estimates specific protein markers present in the woman’s blood sample.
Breast cancer is the most common cancer among women in India with highest numbers in the age group of 50-60. With over 1.5 lakh women being diagnosed with breast cancer, around 70,000 deaths are being reported every year. Taking this into consideration, POC’s technology platform renders testing accessible to 96.3% of women who need to be screened annually. The portable breast cancer screening test, which runs on Pandora CDx technology, uses a simple drop of blood to generate results in 15 minutes. Using multiple cancer markers it claims to exhibit a sensitivity of 0.91and specificity of 1 which implies an accuracy of over 95 per cent and a false positive rate of zero.
At the launch of the device in Maharashtra, State Health minister Dr Deepak Sawant quoted that a pilot is to be run in the state, in the areas where the incidence of breast cancer is high. The acceptance rate of the test is also likely to be more given that it just requires a simple blood test as opposed to exposing of women required for mammography. The taboo of undressing serves as a biggest deterrent for screenings in India, apart from high cost. The operation of the low cost device is easy too, where a technician can operate the machine and data could be sent via mobile devices to a cloud platform. This can then be accessed by a doctor who can contact the patient, explained Sanjeev Saxena, CEO, POC Medical Systems.
Source: POC MedicalSystems via HT
Be the first one to reply
Only logged in users can reply.